Genetron Health Announces Pricing of Initial Public Offering
June 19 2020 - 8:45AM
Genetron Holdings Limited (“Genetron Health” or the “Company”), a
China-based precision oncology company that covers full-cycle
cancer care, today announced the pricing of its initial public
offering of 16,000,000 American Depositary Shares
(“
ADSs”), each representing five ordinary shares
of the Company, at US$16.00 per ADS. The ADSs are expected to begin
trading on the Nasdaq Global Market on June 19, 2020 under the
symbol “GTH.” The gross proceeds from the initial public offering
is US$256 million, assuming the underwriters do not exercise their
over-allotment option to purchase additional ADSs. The Company has
granted the underwriters an option to purchase up to 2,400,000
additional ADSs, which would contribute to additional gross
proceeds of up to US$38.4 million, exercisable within 30 days from
the date of the final prospectus.
Credit Suisse Securities (USA) LLC and China
International Capital Corporation Hong Kong Securities Limited are
acting as joint bookrunners for the offering. BTIG, LLC and
Canaccord Genuity LLC are acting as co-managers.
A registration statement on Form F-1 related to
the offering has been filed with the U.S. Securities and Exchange
Commission (the “SEC”) and declared effective. Copies of the
registration statement can be accessed on the website of the SEC at
www.sec.gov.
The offering is made only by means of a
prospectus forming a part of the effective registration statement.
Copies of the final prospectus relating to this offering, when
available, may be obtained by contacting the following
underwriters: (1) Credit Suisse Securities (USA) LLC, Eleven
Madison Avenue, New York, NY 10010. Attention: Prospectus
Department, telephone: +1-800-221-1037, email:
newyork.prospectus@credit-suisse.com; (2) China International
Capital Corporation Hong Kong Securities Limited, 29th Floor, One
International Finance Centre, 1 Harbour View Street, Central, Hong
Kong. Attention: Rita Lee, telephone: +852-2872-2000, email:
leerita@cicc.com.cn; (3) BTIG, LLC, 65 East 55th Street, New York,
NY 10022. Email: equitycapitalmarkets@btig.com; and (4) Canaccord
Genuity LLC, 99 High Street, 12th Floor, Boston, MA 02110.
Attention: Syndicate Department, telephone: +1-617-371-3900, email:
prospectus@cgf.com.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy the securities
described herein, nor shall there be any sale of these securities
in any state or jurisdiction in which such an offer, solicitation,
or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
About Genetron Holdings
LimitedGenetron Holdings Limited (“Genetron Health” or the
“Company”) is a leading precision oncology platform company in
China that specializes in cancer molecular profiling and harnesses
advanced technologies in molecular biology and data science to
transform cancer treatment. The Company has developed a
comprehensive product and service portfolio that cover the
full-cycle of cancer care from early screening, to diagnosis and
treatment recommendations, to continuous monitoring and continuous
care.
Safe Harbor StatementThis press
release contains forward-looking statements. These statements are
made under the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Statements that are not
historical facts, including statements about the Company’s beliefs
and expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties, and a number
of factors could cause actual results to differ materially from
those contained in any forward-looking statement. In some cases,
forward-looking statements can be identified by words or phrases
such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. Further
information regarding these and other risks, uncertainties or
factors is included in the Company’s filings with the SEC. All
information provided in this press release is as of the date of
this press release, and the Company does not undertake any duty to
update such information, except as required under applicable
law.
Investor Relations
ContactUS:Stephanie CarringtonWestwicke, an ICR
CompanyStephanie.Carrington@westwicke.comOffice: +1 (646)
277-1282
Asia:Bill ZimaICR, Inc.Email:
bill.zima@icrinc.com ir@genetronhealth.com
Media Relations ContactEdmond
LococoICREdmond.Lococo@icrinc.comMobile: +86
138-1079-1408pr@genetronhealth.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024